Iovance Biotherapeutics Inc
NASDAQ: IOVA · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-03
Iovance Biotherapeutics Inc (IOVA) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2008 | — | $-57140.00 | — | — | — |
| 2009 | — | $-15772.00 | — | — | — |
| 2010 | — | $-1.61M | — | — | — |
| 2011 | $0.00 | $-25.69M | — | — | — |
| 2012 | $0.00 | $-3.31M | — | — | — |
| 2013 | $0.00 | $-25.38M | — | — | — |
| 2014 | $0.00 | $-12.04M | — | — | — |
| 2015 | $0.00 | $-27.66M | — | — | — |
| 2016 | $0.00 | $-52.89M | — | — | — |
| 2017 | $0.00 | $-92.06M | — | — | — |
| 2018 | $0.00 | $-123.58M | — | — | — |
| 2019 | $0.00 | $-187.07M | — | — | — |
| 2020 | $0.00 | $-259.58M | — | — | — |
| 2021 | $0.00 | $-327.82M | — | — | — |
| 2022 | $238000.00 | $-389.92M | -8,880.25% | -167,595.80% | -163,833.19% |
| 2023 | $1.19M | $-444.04M | -804.54% | -38,734.99% | -37,345.42% |
| 2024 | $164.07M | $-372.18M | 24.43% | -240.92% | -226.84% |
| 2025 | $263.50M | $-390.98M | 97.23% | -153.08% | -148.38% |
Frequently asked questions
What is Iovance Biotherapeutics Inc's revenue?
Iovance Biotherapeutics Inc's trailing twelve-month revenue is $285.61M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is IOVA?
In its most recent fiscal year, IOVA ran a gross margin of 97.23%, an operating margin of -153.08%, and a net margin of -148.38%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does IOVA generate?
IOVA produced $-336.24M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is IOVA's balance sheet healthy?
IOVA holds $163.08M in cash and equivalents against — in long-term debt, on $698.58M of shareholder equity. That debt is best read against the cash flow the business throws off each year.